See also this year's filing and all EDGAR filings for this company.
PDF Report 0001133416_2014_Galectin_Therapeutics_INC.pdf
Logs
| warning | No LiabilitiesAndStockholdersEquity node found | input.sec.calculation_linkbase.edgar_model_mapping | {'lase_node': None, 'equity_node': None, 'partners_cap_node': None, 'nodes': "NodeView(('AssetsCurrent', 'Assets', 'PropertyPlantAndEquipmentNet', 'RestrictedCashAndCashEquivalentsNoncurrent', 'IntangibleAssetsNetExcludingGoodwill', 'CashAndCashEquivalentsAtCarryingValue', 'PrepaidExpenseAndOtherAssetsCurrent', 'LiabilitiesCurrent', 'Liabilities', 'OtherLiabilitiesNoncurrent', 'AccountsPayableCurrent', 'AccruedLiabilitiesCurrent', 'DividendsPayableCurrent', 'UndesignatedCapitalStockValue', 'StockholdersEquity', 'PreferredStockValue', 'CommonStockValue', 'AdditionalPaidInCapital', 'DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage'))"} |
Graph
Absolute values for 0001133416, Galectin Therapeutics INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 10,687,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 23,000 |
| 2 | PropertyPlantAndEquipmentNet | 3,000 |
| 3 | remainder_Assets | 0 |
| 4 | LiabilitiesCurrent | 2,486,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 6,416,000 |
| 9 | ResearchAndDevelopmentExpense | 5,688,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 16,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 10,713,000 |
| 1 | Liabilities | 2,486,000 |
| 2 | Expenses | 12,104,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 8,227,000 |
| 5 | NetIncome | -12,088,000 |
| 6 | ComprehensiveNetIncome | -12,088,000 |
| 7 | BaseVar | 12,659,500 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 0.886 |
| 9 | EconomicCapitalRatio | 2.21 |
Edgar->Model Mapping
Feature Distribution
Change over Time
